iBio, Inc.
IBIO · NASDAQ
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | 0.00 | 0.00 | 0.89 |
| FCF Yield | -191.22% | -243.68% | -242.05% | -39.81% |
| EV / EBITDA | -0.17 | 0.15 | -0.89 | -4.53 |
| Quality | ||||
| ROIC | -101.16% | -64.36% | -88.32% | -32.55% |
| Gross Margin | 100.00% | 100.00% | 0.00% | -101.22% |
| Cash Conversion Ratio | 0.83 | 0.74 | 0.47 | 1.28 |
| Growth | ||||
| Revenue 3-Year CAGR | – | -50.75% | -100.00% | 4.77% |
| Free Cash Flow Growth | 18.35% | 48.13% | 19.85% | -28.12% |
| Safety | ||||
| Net Debt / EBITDA | 0.30 | 0.70 | -0.35 | -0.12 |
| Interest Coverage | -87.75 | -96.71 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.97 |
| Cash Conversion Cycle | 95.81 | 1,156.64 | 0.00 | 1,146.75 |